🔗 Share this article

While the United States proceeds with sweeping changes to its vaccination recommendations, one figure appears unexpectedly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by questioning COVID-19 vaccines throughout the global health crisis and has focused upon alleged fatalities following Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Program

Public health authorities planned to reveal major revisions to the pediatric immunization program in December, bringing the US with the Danish vaccine program, according to reports – a significant shift that would put the US out of alignment with many the world with no evidence for public health gain. This reveal has been postponed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to speak at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to run the office this year.

A Shift at the Agency

This interim role might represent a tighter collaboration between the drug and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for ending specific pediatric vaccine recommendations in the US to become more like the Danish model, a society with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – rather than drug regulation.

Doubts Over Background

The appointee has no apparent background in medication creation, oversight or administrative roles, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for running the CDER, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a major agency. She has no expertise in drug approvals.”

Past commissioners of the center would “grasp regulatory frameworks and the research of drug development”, commented Janet Woodcock. “Objectively, she doesn’t have the sort of resume that previous people who ran the center have had.”

CDER has an immense portfolio at the agency, she emphasized.

“Everybody just focuses on the new drug program, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and other areas, and every single one need to be managed,” Woodcock explained. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant administrative element to the role, which supervises over 5,000 staff members. “It is a huge administrative position, if you execute it properly,” Woodcock said.

Agency Reaction and Contentious Programs

In response to questions about Dr. Høeg's fitness for the role and whether this assignment represents increased cooperation among regulatory chiefs on vaccines, a press secretary said that the “questions rely on inaccurate assumptions”.

“Her experience aligns with the duties of her role,” the official explained, noting the time Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg inherits the commissioner’s new expedited review system, a controversial rapid medication authorization process that apparently worried her preceding directors. “How are these medications being chosen for this voucher program? Who is making the calls?” Howard questioned. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Overall, he remarked, “the agency appears to be shifting towards more relaxed oversight of most medications, except for immunizations.”

Public Past Work on Immunizations

With immunizations, Høeg has a clearer, if problematic, history, Howard said. She published a research paper using non-validated public submissions to assess the incidence of myocarditis following Covid immunization. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the incoming government encompassed changing rules for recently developed shots and ending “non-essential” immunizations, she stated post-election on a podcast. At the FDA, Høeg has allegedly floated the idea of preventing teenage boys from obtaining Covid vaccines.

“She’s an thorough dogmatist who starts off with her conclusions and tailors the evidence to accommodate the science in a highly misleading, dishonest manner,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg became part of other contrarians, {like|